<unk> s are a type of nonsteroidal anti-inflammatory drug (NSAID) that directly targets cyclooxygenase-2,<unk> -2, an enzyme responsible for inflammation and pain. Targeting selectivity for<unk> -2 reduces the risk of peptic ulceration and is the main feature of celecoxib, rofecoxib, and other members of this drug class. After several<unk> -2-inhibiting drugs were approved for marketing, data from clinical trials revealed that<unk> s caused a significant increase in heart attacks and strokes, with some drugs in the class having worse risks than others. Rofecoxib (sold under the brand name Vioxx) was taken off the market in<unk> 004 because of these concerns, while celecoxib (sold under the brand name Celebrex) and traditional NSAIDs received boxed warnings on their labels. Many<unk> -2-specific inhibitors have been removed from the US market. As of December<unk> 011, only Celebrex (generic name of celecoxib) is still available for purchase in the United States. In the European Union, celecoxib, parecoxib and etoricoxib has been approved for use by the European Medicines Agency.
COX-2 inhibitor
Arachidonate 5-lipoxygenase inhibitor
Reuptake inhibitor
CDK inhibitor
Endopeptidase inhibitor
Histone deacetylase inhibitor
Protein kinase inhibitor
TNF inhibitor